In recent weeks oncology lost two great physician-scientist-leaders, Emil J Freireich and Joseph V. Simone [1, 2]. Comprehensive biographies of both men have appeared (https://ascopost.com/news/february-2021/emil-j-freireich-md-dies-at-93/ and https://blogs.stjude.org/progress/joseph-v-simone-st-jude/) [3, 4]. As a friend and associate of both men, and as a witness and participant in that remarkable period when cancer treatment became a curative reality, I have very vivid and fond memories of both. As it happens, both J (“J” stood for no name—it was just an initial) and Joe came from Chicago, where they were raised in immigrant communities. J's parents immigrated in the 1920s from Hungary. His father died when he was just 2, and he was raised by his mother in relative poverty, but he proved to be a remarkable student, finishing medical school at the University of Illinois at age 22. J pursued further training in Boston at Boston University's Massachusetts Memorial Hospital in the Hematology Department and, in 1955, was recruited to join the National Cancer Institute (NCI) as a junior investigator under Emil J. Frei (Tom). J recalled his first visit to NCI, where he found Tom's name on the door, and thought perhaps they had mistakenly truncated his name, Emil J Freireich. He walked into the office and found a tall string bean sitting at the desk. It was Frei's office. The combination of Frei and Freireich was sensational—the pair creating the first curative multidrug protocols for childhood leukemia and J solving the vexing problem of hemorrhagic deaths with his invention of platelet transfusion made possible by pheresis technology. J witnessed futile attempts to treat sepsis in neutropenic patients and reasoned that early introduction of multidrug broad-spectrum antibiotics in febrile neutropenia could save children during this crucial interval. Together, Frei and Freireich created a format for intensive, and curative, chemotherapy of this disease. At the same time, Don Pinkel and, later, Joe Simone, furthered this work with improved chemotherapy, CNS prophylaxis, and large randomized trials at St. Jude. As described below by Vince DeVita (Frei–Freireich fellow at NCI, 1963–1965), Freireich was forever bombastic, outspoken, and impatiently critical of foolish thinking and cautious skepticism. He knew that the journey to cure required making drastic changes and taking chances. At the same time, he was a warm and supportive mentor and friend to many of the future leaders of oncology as they served in the training programs at NCI and, later, at MD Anderson, where he settled for the remainder of his career in 1965. The list of trainees graduating from his Developmental Therapeutics fellowship at MD Anderson is a virtual Who's Who in Oncology (e.g., Kantarjian, Hortobágyi, McCredie). I visited him several times there and always enjoyed his wide smile, his laugh that shook his mighty torso, and his eloquence. His legacy is the premier leukemia service at MD Anderson, which he nurtured and advised through his later years. Distilling one lesson from my years of friendship with J, I owe the most to those like J and like DeVita and George Canellos who challenged my assumptions and my thinking. In contrast to J, Joe Simone was the quintessential diplomat, organizer, and unifier, in addition to his great ability as a clinical researcher. He brought St. Jude Children's Research Hospital to the highest level of clinical investigation in childhood malignancy during his 25 years as a clinical investigation and 9-year tenure as Director of St. Jude, from 1983 to 1992. Not only was he a significant contributor to the development of total therapy for childhood leukemia, but he recruited a number of first-rate clinical investigators (Hon-Chi Pui, William Evans) and renowned basic scientists (Chuck Sherr, Jim Ihle, and Peter Doherty), and created a billion dollar basic research program. It would be impossible to describe his many contributions as an advisor to NCI and other cancer centers. I personally worked closely with him when he served as a member of the Board of Scientific Counselors of the Division of Cancer Treatment at NCI. We often joked that his family, the Simones, and my mother's family, the Simons, probably shared a common ancestor somewhere in the Mediterranean. His wisdom and stature were immensely valuable in resolving so many issues: giving up a failing investment in neutron therapy, supporting immunotherapy, building an effective pediatric oncology group, supporting natural product research that led to paclitaxel, and establishing comprehensive auditing for NCI-sponsored trials. During his later years at Memorial Sloan Kettering and the Huntsman Cancer Institute, he strengthened the training programs and faculty at these institutions. He was famous for his book of Simone's Maxims, still in print, which advised young academics how to negotiate the treacherous waters of academic medicine [5]. While he reflected that “institutions don't love you back,” certainly the people he mentored and befriended reciprocated that love. Although the contributions of these early oncologists may seem distant in years, they should not be forgotten. We live within the culture of deep commitment to research and devotion to discovery that they created. I came to the NCI as a fellow with Bob Young in 1967, and very much felt embedded in a culture established by Freireich and Frei, and carried forward by their trainees. That culture continues today in the work of the brilliant younger physician-scientists who have carried our field into the molecular age. Without them, without the Freis and Freireichs, the Simones and Pinkels, without DeVita and Canellos and the many other people they trained and mentored, the current practice of oncology would still be sailing to terra incognita. Elizabeth (Vince's daughter and co-author of his book, The Death of Cancer [1]) expresses my feeling about Jay well. After our book was published, I sent Jay a copy, somewhat fearful about how he might take the stories (about J's escapades at NCI). I asked that he read it through to the end, as he was the hero of the book—an inspiration. To me, the stories explained his intensity in work and play. He wrote me a very nice letter saying he enjoyed the book and the stories, and it would occupy an important place on his bookshelf. Deep down, he was a kind person. When he thought you needed adjustment, he could get excited and poke you in the chest with his bony index finger for emphasis. I can still feel the pokes! He was passionate and had the courage of his convictions. He was a great mentor to me. I owe him much. So do a lot of little people who grew up to be big people because of him. Rest In Peace Jay. May a band of little angels sing you to your rest. Martin Murphy joined St. Jude's as an assistant member 6 years after Joe was recruited and was immediately befriended by Joe. Now deputy editor of The Oncologist, Marty and Joe remained friends for the next 4 and half decades. Marty recalls: St. Jude's legendary founding director, Donald Pinkel, recruited Joe in 1967 by saying, “You must have a Moby Dick to chase.” Don had already identified pediatric leukemia as his Moby Dick, but he needed a special leader to recruit, train, and retain like-minded pediatricians. He needed Joe. And it wasn't long before Don promoted Joe to director of St. Jude's signature Leukemia Program. Mind you, it was not seen by many extramural to St. Jude as an enviable promotion, given that pediatric leukemia was at that time considered rarely curable. Indeed, pediatricians who sought to change its inevitable outcome by giving “poisonous chemicals” to children were pilloried at several national meetings, Joe and Don among them. Acute lymphocytic leukemia of childhood was to become their Moby Dick, with Don clearly cast in the role of Captain Ahab and Joe playing half a dozen other crewmembers on St. Jude's Pequod. Most especially, Joe was cast as Ishmael, the man aboard who held much of it together. Joe narrated what was happening and, with a weather eye to leeward, foretold storms that inevitably brewed in the unchartered seas of chemo- and radiation therapy. Joe kept many of us, me especially, out of harm's way. Building on the combination therapies developed by Freireich and Frei at NCI, the St. Jude team added the crucial CNS prophylaxis consolidation and maintenance therapies, and other refinements derived from beautifully sequenced trials that led to the current 90% cure rate of childhood ALL. The good ship St. Jude was joined in convoy to cure by other vessels from major pediatric oncology centers in that voyage. The years 1973–1975 were formative in my career, made more so by Joe's sage advice and fraternal counsel always proffered with honesty and a sense of humor. His outsized impact was on St. Jude's crew who together harpooned Moby Dick. In so doing, Joe helped change the course of cancer history, as many of his little patients lived to make grandparents out of their parents.

Although there has been considerable research activity in the treatment of Hodgkin's lymphoma since advanced stages of the disease became curable with combination chemotherapy in the 1960s, the most significant advances have involved the maintenance of a particular level of antitumor efficacy while acute and late toxic side effects and their attendant mortality are reduced. These advances include the preservation of high response rates at reduced levels of toxicity with the current standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); the demonstration that various forms of radiation therapy were associated with unacceptably high levels of long-term toxicity; the application . . .

The field of medical oncology has lost one of the premier clinical investigators of our time. Gianni Bonadonna passed away on 6 September 2015 after a long history of suffering from a cerebral hemorrhage almost 20 years ago. Gianni was born in 1934 in Milan, where he spent the majority of his professional life. He was a trainee at Memorial Hospital but ascended to the post of Director of Medical Oncology at the Instituto Tumori in 1976, an institution where almost all his clinical researches were undertaken. Vince DeVita and I got to know him when he came to the NCI around 1969–1970, interested in breast cancer. We showed him the results of the CMF(P), which evolved to the CMF regimen which he later adopted to adjuvant therapy of breast cancer. It was being piloted at NCI in advanced disease and showed greater antitumor activity than single agent therapy, which was commonly used at that time. A variety of medico-political factors prevented a random trial of chemotherapy in nodepositive early breast cancer in USA. However, with NCI support, Dr Bonadonna with the CMF regimen proved that early high-risk breast cancer could be benefited by combination chemotherapy compared with no treatment, which was the standard of the time. This began the field of adjuvant therapy of breast cancer which continues to this day. Dr DeVita and I interacted with Gianni even closer because of the chemotherapy of Lymphoma, a major interest of the NCI Medicine Branch at the time. Dr Bonadonna’s team developed the ABVD regimen, which was originally used as a salvage regimen for MOPP relapses of Hodgkin lymphoma but evolved as the current standard primary chemotherapy for Hodgkin lymphoma. Dr Bonadonna was a highly cultured physician with a keen interest in music and art. He was a collector of ancient artifacts and widely traveled to collect them. We considered him one of our closest European colleagues and will sorely miss him.

This article highlights the important collaboration between the U.S. NCI in Bethesda, Maryland and the Istituto Tumori in Milan, Italy that had a major impact on the development of curative regimens for breast cancer, Hodgkin's disease and diffuse large B cell lymphoma.In addition to his contribution to developing new therapies, Gianni Bonadonna played an important role in bringing highly focused, disciplined, ethical clinical trials to the European continent.

Gianni Bonadonna (1934–2015) is fondly remembered. His contributions to the field of oncology are highlighted, including a clinical trial to determine the effects of postoperative combination chemotherapy to prevent relapse of breast cancer, which led to a revolutionary treatment approach using various active agents, and a salvage regimen for the treatment of Hodgkin lymphoma.

Decades after declaring war on the disease, the US needs a second National Cancer Act to finish the job, says Vincent DeVita

Gianni Bonadonna in his laboratory in the mid-1980s. Our friend and colleague Dr. Gianni Bonadonna died on September 7, 2015 at the age of 81 years, severely disabled for 20 years after suffering a near-fatal stroke in 1995. In response, in 1999, he founded the Michelangelo Foundation, of which he was president, and set about with great resilience to contribute to the field of oncology by writing books on his own experience of illness and arguing that we cannot fight cancer if we do not fight with and for the patient. Toward the end, as he dealt with the devastating impact of his illness, he revealed his spiritual side, including a meeting with Pope Francis, whom he greatly admired. To one of us (V.T.D.), he was an energetic peer in a rapidly progressing field. To the other (A.S.), he will always be remembered as a valued mentor. To provide some insight into the world of this beautifully complex man before and after his stroke, we recount in his own words some of the people, places, and events that he believed were most important to him. When the successful trial of cyclophosphamide, methotrexate, and 5-fluorouracil was reported in The New England Journal of Medicine in 1976 in a now-famous article that vaulted Gianni Bonadonna into the world of oncology giants,1 an accompanying editorial by an admiring colleague claimed that in Milan there was another icon like the La Scala Opera House.2 And in many ways there was. Although he fully embraced the language and culture of North America, Dr. Bonadonna was at his core a quintessential Italian gentleman and that is how the world of oncology viewed him. His style in dressing and narrating fascinated colleagues all over the world; his elegant apparel was always a part of how most of us saw Gianni. He was also well steeped in music, opera, art, poetry, and movies, and deeply valued his true friendships. Dr. Bonadonna was born in Milan, Italy in 1934, where he studied and graduated from medical school. After a short period in Canada and then at Cabrini Medical Center in New York City, he started his career as a medical oncologist at what was then called Memorial Hospital for Cancer and Allied Diseases and is now known as Memorial Sloan Kettering Cancer Center (MSKCC). Years later, Dr. DeVita was physician-in-chief and Dr. Surbone became an associate attending physician. When Dr. Surbone left his department in Milan to join MSKCC, Gianni told her that those were the best years of his life, where everything seemed easy, maybe because he was younger or because he worked hard and well. The influence of Dr. Bonadonna's training at Memorial Hospital had a deep and lasting impact on both him and the field of oncology in Italy. He directed the first Italian department of medical oncology at the National Cancer Institute (Istituto Nazionale dei Tumori) in Milan as if he were in New York City. At a time when Italian medicine was still governed by paternalism and suspicion of rigorous methodologies, he set an example by running clinical trials, also in collaboration with the National Cancer Institute in Bethesda, Maryland, where patients were informed of their disease and the experimental nature of treatments, nurses and physicians were equally respected, women were among his closest collaborators, and young physicians were treated as partners in research and day-to-day decision-making. His admiration for his mentor at MSKCC, Dr. David A. Karnofsky, was also profound. “David A. Karnofsky was gifted with an open and tolerant mind of the true man of science. He was gentle and shy; yet he held strong opinions and expressed them strongly. Karnofsky's approach to clinical oncology was that of the laboratory scientist and he never conceived that any step he took would lead to a final and permanent result.”3 Given his admiration for Dr. Karnofsky, being selected to give the David A. Karnofsky Memorial Award and Lecture at the American Society of Clinical Oncology 25th annual meeting in 1989 was a special honor for Dr. Bonadonna. In the lecture, he unraveled the steps he foresaw toward a cure for breast cancer, from the first development of adjuvant therapy with cyclophosphamide, methotrexate, and 5-fluorouracil to the state of the art in 1988, a revelation at the time. In his conclusion, he gave another nod toward his mentor by saying “There is still a large gap between the prophecies of great achievement and the realities of the clinical situation. However, among so many difficulties, it is appropriate to remember that in all good and legitimate enterprises, time, the action itself, and the help of Heaven usually disclose thousands of new pathways and reveal thousands of unsuspected advantages… This has been the experience of David Karnofsky as well as our own.”3 He recounted his memory of the response to his lecture in one of his books written after his stroke: “The silence was astonishing…the standing ovation endless. Only You, Eternal Father, could become jealous of such a standing ovation!”4 In that last book, Meeting With the Eternal Father, he decided to restart a conversation with God, which he had interrupted after his younger years. “I fight, think and try to narrate myself hoping that You will benevolently listen to me and look at my life and make me believe that You are here.”4 Dear Vince, The time around the New Year is always a time of memories not always pleasant except for our unbreakable friendship. I am fine, and every day I go to my office and keep on writing. As long as I can, I want to do as Sir Winston Churchill said: “We will never surrender!” Gianni “Keep in touch,” he ended his last e-mail to Dr. Surbone, written 2 days before he passed away. And we all will, Gianni, through your writings. Your life was rich, successful, humane, and worth living. Thank you for setting an example in professional excellence and in courage.

DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 10e - Libros de Medicina - Oncologia general - 250,00

Cancer Principle & Practice of oncology , Cancer Principle & Practice of oncology , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

Understand and apply the scientific advances that are revolutionizing cancer research and practice with Cancer: Principles and Practice of Oncology: Primer of the Molecular Biology of Cancer. Derived from DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology - widely hailed as the definitive clinical reference in oncology - the second editon of this popular Primer focuses on the molecular biology information that is of critical importance to research scientists and clinical oncologists alike.* Get up-to-date, dependable coverage of every important frontier in aspect of the molecular biology of cancer with contributions from a noteworthy roster of leading scientists and clinicians, featuring an updated version of the classic Hallmarks of Cancer by Hanahan and Weinberg* See how molecular biology advances are impacting clinical practice with separate chapters on each of the 19 most common cancer types.* Navigate the challenges and ethical dilemmas of cancer genetics with a thorough section chapters on genetic counseling and genetic testing.Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to:*Complete content with enhanced navigation* A powerful search that pulls results from content in the book, your notes, and even the web*Cross-linked pages, references, and more for easy navigation*Highlighting tool for easier reference of key content throughout the text* Ability to take and share notes with friends and colleagues*Quick reference tabbing to save your favorite content for future use

George P. Canellos, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Saul A. Rosenberg, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA Jonathan W. Friedberg, James P. Wilmont Cancer Center, University of Rochester, Rochester, NY T. Andrew Lister, Barts Cancer Institute, University of London, London, United Kingdom Vincent T. DeVita, Yale Cancer Center, Yale University School of Medicine, New Haven, CT

The prognosis of patients with Hodgkin’s disease has dramatically improved over the past few decades. Treatment with currently standard radiotherapy or combination chemotherapy programmes will result in durable complete remissions and probable cure in most patients. However, these programmes are intensive, technically demanding, and associated with a risk of certain acute side effects and long term complications which vary in nature and severity according to the specific therapy employed.

This overview of 200 years of research and progress in the field of cancer provides support for the value of patience and investment in research.

The Cancer Act that was signed by President Nixon in December 1971 had a mandate "to support research and the application of the results of research, to reduce the incidence, morbidity and mortality from cancer." It has succeeded in many of these aims, as this personal account testifies.

2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.

2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.